10-K · March 27, 2026
Hoth Therapeutics, Inc. experienced a challenging year in 2025, continuing to report significant net losses totaling approximately $12.5 million, in contrast to $8.2 million in the previous year. Cash and cash…
Earnings analysis · 10-Q
RKTO earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text contains no income statement, balance sheet, cash-flow, segment, or EPS data, so quarterly financial trends cannot be assessed. The filing emphasizes that Rocket One’s three core platforms remain…
Read full summary
The extracted 10-Q text contains no income statement, balance sheet, cash-flow, segment, or EPS data, so quarterly financial trends cannot be assessed. The filing emphasizes that Rocket One’s three core platforms remain early-stage and have not been validated in commercial products, while also warning of significant capital requirements and an industry-wide memory shortage. The Company issued 500,000 shares on May 14, 2026 and 60,000 shares on June 10, 2026 for business development and consulting services. Management reported effective disclosure controls as of June 30, 2026 and no material changes to previously disclosed risk factors.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls deemed effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
Equity issued for services
The Company issued 500,000 shares on May 14, 2026 and 60,000 shares on June 10, 2026 for business development and consulting services, increasing potential equity dilution.
-
Three platforms under development
The Company has three core platforms—the nanomagnetic matrix multiplier, skyrmion-mediated spintronic memory, and Swarm Stage AI—under exclusive license agreements with Virginia Commonwealth University Intellectual Property Foundation.
-
No material litigation disclosed
The Company reported no material legal proceedings and no pending or threatened proceeding believed likely to have a material adverse effect on its business, results, cash flows, or financial condition.
What to watch
-
Commercialization remains unproven
The filing states there have been no material changes to risk factors from the Annual Report or other filings. The Company identifies three core platforms as early-stage and validated only in laboratory or simulation environments, not in commercial products.
-
High development capital needs
The Company states that its initiatives require substantial and ongoing investments and that it expects to incur significant capital expenditures before products or services become profitable, which may never occur.
-
Memory supply and cost pressure
The Company discloses an industry-wide memory shortage, with demand outpacing supply and memory prices increasing as a result; shortages or higher input costs could materially harm operations.
Management's outlook
No quantitative revenue or EPS guidance, outlook, or liquidity outlook was provided in the extracted filing. The filing states that there were no material changes to previously disclosed risk factors.
Earlier filings 3
10-Q · November 12, 2025
RKTO reported a net loss of approximately $4.11 million for the three months ended September 30, 2025, marking a significant increase in losses compared to $2.2 million for the same period last year. General and…
10-Q · August 12, 2025
RKTO reported a net loss of approximately $2.2 million for Q2 2025, widening from a net loss of $1.7 million in Q2 2024. R&D spending increased notably, reaching $1.0 million, a 67% rise year-over-year from $0.6…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.